West Pharmaceutical Services, Inc. (WST)

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In West Pharmaceuticals (WST) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in West between February 16, 2023 to February 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown dividends at 19.1% annually over five years, with many trading at significant discounts. Recent changes include six new additions, with expected long-term CAGRs near 20% based on dividend yield theory and valuation metrics.

West Pharmaceutical Services, Inc. (NYSE:WST ) Bank of America Global Healthcare Conference 2025 September 24, 2025 10:05 AM EDT Company Participants Eric Green - Non-Independent Chair of the Board, President & CEO Robert McMahon - Senior VP & CFO Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us for our next session. My name is Mike Ryskin.

WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

West Pharmaceutical Services, Inc. (WST) Presents At Wells Fargo 2025 Healthcare Conference (Transcript)

EXTON, Pa. , Aug. 21, 2025 /PRNewswire/ --  West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at multiple investor conferences in September.  Here are the details of the presentations: Wells Fargo 2025 Healthcare Conference: Fireside chat at 3:00 PM ET on Wednesday, September 3, 2025 in Boston, MA.

The mean of analysts' price targets for West Pharmaceutical (WST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs now provide a powerful, sustained growth catalyst beyond the company's traditional biologics and injectable therapeutics exposure. Risks include elevated valuation, potential competition, and the threat of oral GLP-1 formulations or healthcare policy changes impacting future growth.

The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached their fiduciary duties to shareholders.

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.

My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net profit margin in 2024.

West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Bernard J. Birkett - Senior VP & CFO Eric M.

West Pharmaceutical Services (WST 20.87%), a global manufacturer of drug packaging and delivery systems for the pharmaceutical and healthcare industries, reported Q2 2025 earnings on July 24, 2025. The key news was a significant beat on both GAAP revenue and non-GAAP EPS.